An IQVIA Virtual Conference for Emerging Biopharma Companies

IQVIA will host three sessions with content addressing the specific needs and challenges of emerging biopharma companies. The sessions will provide an understanding of how they can leverage real-world evidence (RWE) from early clinical development through commercialization to accelerate patient access to innovative treatments and demonstrate value to investors.

Understand the benefits of end-to-end RWE generation throughout the product lifecycle including:

Pre-clinical
e.g. natural history of disease studies
Clinical development
e.g. increase efficiencies and de-risk development plans
Pre-launch regulatory engagement
e.g. use of RWE to complement trial data or serve as a comparator arm
Market optimization needs post-launch
e.g. RWE for payer coverage considerations

Registration is now open. Follow this link to learn more about each session and to register: https://www.events.iqvia.com/EBP22